Bausch Health Companies Inc (NYSE: BHC) |
|
Price: $6.4500
$-0.09
-1.376%
|
Day's High:
| $6.66
| Week Perf:
| -11.4 %
|
Day's Low: |
$ 6.25 |
30 Day Perf: |
-17.83 % |
Volume (M): |
1,791 |
52 Wk High: |
$ 11.46 |
Volume (M$): |
$ 11,551 |
52 Wk Avg: |
$7.68 |
Open: |
$6.48 |
52 Wk Low: |
$3.96 |
|
|
Market Capitalization (Millions $) |
2,376 |
Shares
Outstanding (Millions) |
368 |
Employees |
20,270 |
Revenues (TTM) (Millions $) |
9,474 |
Net Income (TTM) (Millions $) |
-217 |
Cash Flow (TTM) (Millions $) |
-30 |
Capital Exp. (TTM) (Millions $) |
377 |
Bausch Health Companies Inc
Bausch Health Companies Inc. (formerly known as Valeant Pharmaceuticals International Inc.) is a multinational pharmaceutical company that was founded in 1960 and is based in Laval, Canada. The company focuses on innovative pharmaceutical products and medical devices for the treatment of eye health, gastroenterology, dermatology, and aesthetics. Bausch Health operates in more than 100 countries, selling products to healthcare providers and patients around the world.
Bausch Health has a diverse portfolio of products, including prescription drugs, over-the-counter medications, contact lenses, surgical instruments, and biologic drugs. The company has a number of strong brands, including Bausch + Lomb, Salix Pharmaceuticals, and Ortho Dermatologics. Bausch + Lomb is a leading global eye health business that offers contact lenses, ocular drugs, and surgical instruments. Salix Pharmaceuticals is a specialized gastroenterology company that offers treatments for gastrointestinal diseases. Ortho Dermatologics offers prescription dermatology products.
Bausch Health is committed to research and development, spending significant resources on developing new products and improving existing ones. The company has a strong pipeline of products, and it invests heavily in clinical trials to ensure that its products are effective and safe.
Bausch Health has faced regulatory and legal challenges in the past, including allegations of accounting fraud and price gouging for some of its drugs. In response, the company has implemented a number of reforms, including changes to its governance structure and pricing policies.
Overall, Bausch Health Companies Inc. is a major player in the pharmaceutical industry, with a diverse portfolio of products and a strong commitment to research and development. The company has faced challenges in the past but has taken steps to improve its reputation and ensure that its products are accessible and affordable for patients.
Company Address: 2150 St. Elzéar Blvd. West Laval 0 QC
Company Phone Number: 744-6792 Stock Exchange / Ticker: NYSE BHC
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Stocks on the Move
Published Fri, Jul 26 2024 7:20 PM UTC
The recent performance of Bausch Health Companies Inc., which has lagged behind the broader market by nearly 17.89% so far this year, reflects a multitude of factors, from financial instability to persistent rumors of bankruptcy. After suffering a staggering decline of over 40% in stock value amidst swirling speculation regarding its financial health, Bausch Health s managem...
|
Bausch Health Companies Inc
As a financial analyst covering Bausch Health Companies Inc, it is clear that the company has faced some challenges in the first quarter of 2024, despite a significant increase in revenue. While the revenue growth of 10.75% from the previous year is certainly a positive sign, the fact that the company reported a net deficit of $77 million is a cause for concern. It is important to note, however, that this deficit is significantly lower than the $209 million deficit reported in the same period last year. Additionally, operating earnings rose by 60.57%, indicating that the company is making progress in improving its business operations.
|
Bausch Health Companies Inc
In a time of uncertainty and fluctuation, the stock market can often feel like a turbulent rollercoaster ride. But amidst the ups and downs, there are companies that continue to strive for success and make impressive strides forward. One such company is Bausch Health Companies Inc, whose recent financial report for the third quarter of 2023 showcases their tenacity and determination in the face of challenges. Despite an increase in revenue of 9.384% year on year, reaching $2.24 billion, Bausch Health Companies Inc unfortunately fell short of reaching break-even point, posting a loss per share of $-1.03. While this may seem disappointing on the surface, it's important to note that Bausch's revenue growth in the third quarter far surpassed their counterparts in the Major Pharmaceutical Preparations sector, who only experienced a 1.30% rise during the same time period. This is a testament to Bausch's ability to not only weather the storm but also outperform their competitors.
|
Bausch Health Companies Inc
Bausch Health Companies Inc, formerly known as Valeant Pharmaceuticals International, is a major player in the pharmaceutical industry. The company recently released its second-quarter earnings for 2023, showing a significant improvement in financial performance compared to the previous year. In the second quarter of 2023, Bausch Health Companies Inc reported a positive earnings per share (EPS) of $0.07, compared to a loss per share of $-0.40 in the same period a year ago. The company's EPS also showed improvement from the preceding quarter, as it turned positive from $-0.55 per share. This turnaround in income is a positive sign for the company and indicates its ability to generate profits.
|
Bausch Health Companies Inc
Bausch Health Companies Inc. has recently reported their financial results for the quarter ending March 31, 2023. The company's diminishing returns increased to $-0.55 per share compared to $-0.19 from the previous year, indicating a decline in their financial performance over time. However, there was an improvement in earnings per share (EPS), which was $-1.13 per share from the prior quarter. The company's revenue grew marginally by 1.356% to $1.94 billion from $1.92 billion in the corresponding quarter a year before. However, there was a significant decline in sequentially revenue by -11.354% from $2.19 billion. This suggests that the company's business operations are not performing as expected and indicates the need for improvement.
|
Per Share |
Current |
Earnings (TTM) |
-0.48 $ |
Revenues (TTM) |
25.72 $
|
Cash Flow (TTM) |
- |
Cash |
1.95 $
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.48 $
|
Revenues (TTM) |
25.72 $ |
Cash Flow (TTM) |
- |
Cash |
1.95 $
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
Salix |
|
25.58 % |
of total Revenue |
International |
|
11.59 % |
of total Revenue |
Solta Medical |
|
4.46 % |
of total Revenue |
Diversified |
|
10.72 % |
of total Revenue |
Bausch Lomb |
|
47.65 % |
of total Revenue |
Segment |
|
100 % |
of total Revenue |
Pharmaceuticals |
|
47.73 % |
of total Revenue |
Devices |
|
22.59 % |
of total Revenue |
OTC |
|
18.8 % |
of total Revenue |
Branded and Other Generics |
|
9.76 % |
of total Revenue |
Other revenues |
|
1.12 % |
of total Revenue |
Salix Pharmaceuticals |
|
25.58 % |
of total Revenue |
International Pharmaceuticals |
|
2.51 % |
of total Revenue |
International OTC |
|
1.99 % |
of total Revenue |
International Branded and Other Generics |
|
6.41 % |
of total Revenue |
International Other revenues |
|
0.68 % |
of total Revenue |
Solta Medical Devices |
|
4.46 % |
of total Revenue |
Diversified Pharmaceuticals |
|
9.8 % |
of total Revenue |
Diversified OTC |
|
0.08 % |
of total Revenue |
Diversified Branded and Other Generics |
|
0.56 % |
of total Revenue |
Diversified Other revenues |
|
0.28 % |
of total Revenue |
Bausch Lomb Pharmaceuticals |
|
9.84 % |
of total Revenue |
Bausch Lomb Devices |
|
18.13 % |
of total Revenue |
Bausch Lomb OTC |
|
16.73 % |
of total Revenue |
Bausch Lomb Branded and Other Generics |
|
2.79 % |
of total Revenue |
Bausch Lomb Other revenues |
|
0.16 % |
of total Revenue |
U S and Puerto Rico |
|
61.16 % |
of total Revenue |
China |
|
5.26 % |
of total Revenue |
Canada |
|
4.14 % |
of total Revenue |
Poland |
|
3.67 % |
of total Revenue |
Mexico |
|
3.51 % |
of total Revenue |
France |
|
2.07 % |
of total Revenue |
Japan |
|
1.83 % |
of total Revenue |
Russia |
|
1.67 % |
of total Revenue |
Germany |
|
1.59 % |
of total Revenue |
South Korea |
|
1.51 % |
of total Revenue |
United Kingdom |
|
1.35 % |
of total Revenue |
Italy |
|
0.92 % |
of total Revenue |
Spain |
|
0.84 % |
of total Revenue |
Other |
|
10.48 % |
of total Revenue |
|
|